Evidence map›Paper›PMID 40074969›Full record

Observational studyClinical drug investigation2025

Frequency of Acute Kidney Injury After the Initiation of Vitamin D Receptor Activators: A Multicenter Retrospective Observational Study.

Masanori Nakanishi, Tomohiro Mizuno, Shinya Sakai, Daiki Hira, Takenao Koseki, Takeshi Matsubara, Hideki Yokoi, Motoko Yanagita, Tomohiro Terada, Shigeki Yamada and 1 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in Clinical drug investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Masanori Nakanishi *Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Kutsukakecho Dengakugakubo 1-98, Toyoake, Aichi, 470-1101, Japan.
Tomohiro Mizuno *Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Kutsukakecho Dengakugakubo 1-98, Toyoake, Aichi, 470-1101, Japan. tomohiro.mizuno@fujita-hu.ac.jp.ORCID http://orcid.org/0000-0001-8203-392X
Shinya SakaiDepartment of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Daiki HiraDepartment of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Takenao KosekiDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Kutsukakecho Dengakugakubo 1-98, Toyoake, Aichi, 470-1101, Japan.
Takeshi MatsubaraDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hideki YokoiDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Motoko YanagitaDepartment of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Tomohiro TeradaDepartment of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto, Japan.
Shigeki YamadaDepartment of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine, Kutsukakecho Dengakugakubo 1-98, Toyoake, Aichi, 470-1101, Japan.
Naotake TsuboiDepartment of Nephrology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesVitamin D receptor activators (VDRAs) are widely used in patients with osteoporosis; however, the frequency of acute kidney injury (AKI) due to VDRAs is unclear. This study aimed to investigate whether the incidence of AKI after VDRA initiation differed among patients with different renal functions.

methodsThe medical records of Japanese patients who were newly prescribed with VDRAs for osteoporosis at the Fujita Health University Hospital or Kyoto University Hospital between April 2012 and March 2022 were retrospectively reviewed in this study. The RIFLE (Risk, Injury, Failure, Loss of function, End-stage kidney disease) criteria were used to assess the incidence of AKI within 7 days after initiation of VDRA therapy. Additionally, the AKI algorithm was used to assess the incidence of AKI from 8 to 365 days after initiation of VDRA therapy.

resultsThe incidence of AKI, as defined by the RIFLE criteria, was significantly higher in patients with normal renal function or end-stage renal failure than in those with mild renal decline (p < 0.05); the incidence of AKI, defined using the AKI algorithm, showed a similar trend. We found that the lack of serum calcium level monitoring before the initiation of VDRAs might be a risk factor for AKI defined by the RIFLE criteria (odds ratio = 2.004, p = 0.096).

conclusionsThe incidence of AKI after the initiation of VDRA therapy was high, even if renal function was normal. Thus, our results suggest that monitoring serum calcium levels before the initiation of VDRA therapy is necessary, regardless of renal function.

Indexed as

Acute Kidney InjuryBone Density Conservation AgentsOsteoporosisReceptors, CalcitriolAgedAged, 80 and overCalciumFemaleHumansIncidenceJapanMaleMiddle AgedRetrospective StudiesRisk FactorsBone Density Conservation AgentsCalciumReceptors, Calcitriol

Identifiers

PMID40074969

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.